Does Neupogen treat low white blood cells?
Yes, Neupogen (filgrastim) treats low white blood cells, specifically neutropenia. It stimulates bone marrow to produce neutrophils, a type of white blood cell, in patients undergoing chemotherapy, bone marrow transplants, or with severe chronic neutropenia.[1]
How does Neupogen work?
Neupogen is a granulocyte colony-stimulating factor (G-CSF) that binds to receptors on precursor cells in the bone marrow, promoting their growth into neutrophils. This raises neutrophil counts within days of injection, reducing infection risk from chemotherapy-induced neutropenia.[1][2]
What conditions is it approved for?
FDA approvals include:
- Neutropenia from cancer chemotherapy.
- Mobilizing stem cells for transplants.
- Congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia.[1]
Off-label uses sometimes cover aplastic anemia or HIV-related neutropenia, but evidence varies.[2]
Common side effects and risks
Most frequent: bone pain, back pain, nausea. Serious risks include acute respiratory distress syndrome, splenic rupture, or allergic reactions. Patients with sickle cell disease face higher risks.[1][2]
How does it compare to Neulasta?
Neulasta (pegfilgrastim) is a longer-acting version of filgrastim, given once per chemotherapy cycle versus daily Neupogen shots. Both boost neutrophils, but Neulasta reduces dosing frequency.[2]
Biosimilars and alternatives
Zarxio (filgrastim-sndz) is the first FDA-approved Neupogen biosimilar, interchangeable and cheaper. Other G-CSF options: Nivestym, Udenyca (pegfilgrastim-cbqv). Check DrugPatentWatch.com for patent status on Neupogen and biosimilars.[3]
When does Neupogen's patent expire?
Original patents expired in the 2000s; biosimilar entry began 2015. Remaining formulation patents expire around 2025-2030, per DrugPatentWatch.com.[3]
[1] FDA Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103353s5149lbl.pdf
[2] UpToDate: Filgrastim and pegfilgrastim overview
[3] DrugPatentWatch.com: https://www.drugpatentwatch.com/p/tradename/NEUPOGEN